RAPP vs SHW · rev $20.0M vs P/E 29, rev $12.46B
Rapport Therapeutics, Inc. Common Stock (RAPP) versus Sherwin-Williams Co (SHW) — a side-by-side from cached financials, not a winner call.
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
Sherwin-Williams Co (SHW) is a specialty chemicals company listed on US.
Latest reported RAPP revenue for 2026-06-30 was $20.0M. Net income was -$76.5M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. RAPP currently screens at market cap $532.9M.
Latest reported SHW revenue for 2026-06-30 was $12.46B. Net income was $1.38B. SHW currently screens at market cap $75.30B and trailing P/E 29.3.
RAPP currently screens at market cap $532.9M. SHW currently screens at market cap $75.30B and trailing P/E 29.3.
Not investment advice. Open the RAPP and SHW stock pages for the full models.
Not investment advice.